An immune-competent lung-on-a-chip for modelling the human severe influenza infection response.

Summary

A microvascularized, immune-competent human lung-on-a-chip recapitulated key features of severe H1N1 infection, including cytokine storm and epithelial injury. The study identified opposing roles of IL-1β and TNF-α and a stromal–immune CXCL12–CXCR4 axis as critical regulators, offering mechanistic targets for therapy development.

Key Findings

• Developed an immune-competent, microvascularized human small-airway lung-on-a-chip that reproduces cytokine storm, immune cell activation, and epithelial damage during severe H1N1 infection.
• Demonstrated opposing roles of IL-1β and TNF-α in initiating and regulating the cytokine storm.
• Identified a critical stromal–immune CXCL12–CXCR4 interaction as a regulator of the host response.

Clinical Implications

While not directly practice-changing, the model supports rational design of targeted immunomodulation (for example, balancing IL-1β and TNF-α signaling or disrupting CXCL12–CXCR4) and could de-risk therapies before clinical trials, potentially accelerating interventions for severe viral pneumonia.

Limitations

• In vitro platform lacks full systemic immune and neurohumoral interactions.
• Findings require validation across viral strains and in vivo/clinical settings.

Future Directions

Leverage the platform to test targeted immunomodulators (e.g., IL-1 blockers, TNF modulators, CXCR4 antagonists) and vaccine candidates, and integrate patient-derived cells to model inter-individual variability.